- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Vagus nerve stimulator placement tied to post operative seizure freedom in children 6 years old or younger
VNS implantation for patients younger than 4 years of age with generalized onset MRE has not been approved by the FDA. This retrospective study establishes feasibility, illustrates an acceptable safety profile in children younger than 6 years, and demonstrates efficacy comparable to that reported in older patients.
Vagus nerve stimulation is an established, effective treatment for medically refractory epilepsy (MRE). In adults, reduction or elimination of seizures occurs in 65%–70% of patients who are implanted with a vagus nerve stimulator (VNS) after stimulation parameters are optimized. Other observed improvements in adults have included improved alertness (58%–63%), mood (45%), and memory (30%–38%).
Vagus nerve stimulation has similarly been used effectively in children. Multiple single-institution, noncontrolled, observational pediatric studies have demonstrated its effectiveness against a wide range of seizure semiologies. Additional benefits include greater alertness and responsiveness and increased overall school performance (29%–39%). Complications have been observed in 3%–11% of patients but are generally self-limited or minor.
Food and Drug Administration (FDA) approval for VNS placement in populations younger than 12 years, however, took 20 years after the initial approval of vagus nerve stimulation. In 1997, vagus nerve stimulation was only approved for adult and pediatric patients older than age 12 years with MRE. In 2017, the FDA extended the use of the LivaNova VNS system to patients older than 4 years with partial-onset seizures that were also medically refractory. Severe generalized seizures, however, are common in young childhood, and vagus nerve stimulation has demonstrated effectiveness and safety in limited, uncontrolled case series.
The study by Maleknia et al published in Journal of Neurosurgery Paediatrics,evaluates a large cohort of children younger than 6 years of age with a mean follow-up > 8 years. The study is the first review of VNS placement in children 6 years and younger with a mean follow-up > 8 years. Despite the longer-term follow-up, their study demonstrates ≥ 50% reduction in seizures. This is in accordance with the seizure reduction rates seen in prior literature with older patients.
There is a promising double-blind randomized controlled trial underway in China to evaluate the differences in efficacy and safety with versus without VNS treatment in children between the ages of 3 and 6 years with MRE. Like the current study, this trial will test the age range currently accepted for VNS placement.
“Based on our patient cohort, VNS placement in young children can be efficacious and safe for treatment of MRE. Vagus nerve stimulation can and should be used as an adjunctive therapy for children with MRE to reduce seizure frequency over a 5-year time span,” conclude the authors.
Reference
Postoperative seizure freedom after vagus nerve stimulator placement in children 6 years of age and younger
Pedram Maleknia MBA, Timothy D. McWilliams BA, Ariana Barkley MD, Dagoberto Estevez-Ordonez MD, Curtis Rozzelle MD, and Jeffrey P. Blount MD, MPH
J Neurosurg Pediatr 31:329–332, 2023
DOI link: https://doi.org/10.3171/2022.12.PEDS22302
MBBS, DrNB Neurosurgery
Krishna Shah, MBBS, DrNB Neurosurgery. She did her MBBS from GMC, Jamnagar, and there after did direct 6 Year DrNB Neurosurgery from Sir Ganga Ram Hospital, Delhi. Her interests lie in Brain and Spine surgery, Neurological disorders, minimally invasive surgeries, Endoscopic brain and spine procedures, as well as research.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751